Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B.

Published byJarod Yelvington Modified over 9 years ago

Similar presentations

Presentation on theme: "Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B."— Presentation transcript:

1 Supplemental Figure 1

2 Supplemental Figure 2

3 Supplemental Figure 3 A B

4 OCI-AML3 IgG ControlControl2501000 nM SP2509, 24 h CD86 MOLM13 CD86 Supplemental Figure 4 A B

5 MV4-11 SP2509 + PS combination indices SP2509PSFaCI(nM) 5002.50.4630.541 60030.5550.452 7503.750.6180.438 80040.6070.489 9004.50.630.500 100050.7050.399 MV4-11 SP2509 + PS 00.20.40.60.81.0 0 0.5 1.0 1.5 Fractional Effect CI C Supplemental Figure 5 OCI-AML3 SP2509 + PS combination indices SP2509PSFaCI(nM) 50050.2940.927 60060.4860.757 7507.50.6680.666 80080.6590.724 90090.7230.708 1000100.7620.716 MOLM13 SP2509 + PS combination indices SP2509PSFaCI(nM) 50050.3960.759 60060.4670.671 7507.50.4340.963 80080.5840.565 90090.5640.687 1000100.6240.605 A B Primary CD34+ CD38- Lin- AML combination indices SP2509 (nM) PS (nM) FaCI 225100.4040.719 250100.5810.407 500100.570.458 600100.580.449 750100.5980.428 1000100.6350.379 D

6 B * OCI-AML3 p21 p16 EZH2 C/EBPα p42 C/EBPα p30 LSD1 SUZ12 β-Actin 250 nM SP2509, 96 h 5 nM PS, 96 h - - + + - + A Supplemental Figure 6

7 Supplemental Figure 7 Primary AML SP2509 and PS SP2509 (nM) PS (nM) EffectCI 250.0 10.0 0.466 0.19902 500.0 10.0 0.541 0.10616 600.0 10.0 0.540 0.11361 750.0 10.0 0.567 0.09734 900.0 10.0 0.573 0.10096 1000.0 10.0 0.608 0.07777 A B

Download ppt "Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B."

Similar presentations

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.
Feedback loop (CV changes input) SP Controller Gc Plant Gp Sensor Gs E MV (Manipulated Variable CV Controlled Variable +-+- S.

Feedback loop (CV changes input) SP Controller Gc Plant Gp Sensor Gs E MV (Manipulated Variable CV Controlled Variable +-+- S.
Supplementary Figure 1 Select oncogenic target of interest Choose an oncogene-driven cell line and a cell line to be used as a counterscreen OCI-AML3 Ba/F3-NRAS-G12D.

Supplementary Figure 1 Select oncogenic target of interest Choose an oncogene-driven cell line and a cell line to be used as a counterscreen OCI-AML3 Ba/F3-NRAS-G12D.
Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
CD68 NE-SSE NE-NS Figure E1. Nrf2 42-kD  actin 32-kD HO-1 100-kD Control si RNA si RNA Nrf2 Control si RNA si RNA Nrf2 Control si RNA si RNA Nrf2 Control.

CD68 NE-SSE NE-NS Figure E1. Nrf2 42-kD  actin 32-kD HO kD Control si RNA si RNA Nrf2 Control si RNA si RNA Nrf2 Control si RNA si RNA Nrf2 Control.
P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
People Fractions. Problem 1 of 20 Answer 1 = 10 Problem 2 of 20 Answer 2 = 5.

People Fractions. Problem 1 of 20 Answer 1 = 10 Problem 2 of 20 Answer 2 = 5.
Serum dilution OD 405 nm PNAG CP5 CP8 AB C Supplemental Figure 1: ELISA analysis of IgG antibody binding in the pre-immune sera of the 9 groups of mice.

Serum dilution OD 405 nm PNAG CP5 CP8 AB C Supplemental Figure 1: ELISA analysis of IgG antibody binding in the pre-immune sera of the 9 groups of mice.
Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.

Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.
Herceptin + 17-AAG Combination BT-474 Tumors

Herceptin + 17-AAG Combination BT-474 Tumors
Supplemental Figure 1 A B panobinostat.

Supplemental Figure 1 A B panobinostat.
Supplemental Figure 1 Auranofin BSO Zn-BG ABC D carfilzomib.

Supplemental Figure 1 Auranofin BSO Zn-BG ABC D carfilzomib.
The exponent is most often used in the power of monomials.

The exponent is most often used in the power of monomials.
Unexpected additional thyroid cancer in a patient with already known cervical cancer detected on PET/CT Kaohsiung Veterans General Hospital Kuan-Hsiu Lin,

Unexpected additional thyroid cancer in a patient with already known cervical cancer detected on PET/CT Kaohsiung Veterans General Hospital Kuan-Hsiu Lin,
Fractions and Decimal Fractions. 1 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 Fractions Decimal Fractions 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0.

Fractions and Decimal Fractions Fractions Decimal Fractions
Practice using fractions, decimals, and percents with place value, number lines, shaded shapes, and shaded 10 x 10 grids.

Practice using fractions, decimals, and percents with place value, number lines, shaded shapes, and shaded 10 x 10 grids.
親愛的吉姆舅舅： 今天吃完晚餐後，奶奶說，在家 裡情況變好以前，您要我搬到城裡跟 您住。奶奶有沒有跟您說，爸爸已經 好久沒有工作，也好久沒有人請媽媽 做衣服了？ 我們聽完都哭了，連爸爸也哭了， 但是媽媽說了一個故事讓我們又笑了。 她說：您們小的時候，她曾經被您追 得爬到樹上去，真的嗎？ 雖然我個子小，但是我很強壯，

親愛的吉姆舅舅： 今天吃完晚餐後，奶奶說，在家 裡情況變好以前，您要我搬到城裡跟 您住。奶奶有沒有跟您說，爸爸已經 好久沒有工作，也好久沒有人請媽媽 做衣服了？ 我們聽完都哭了，連爸爸也哭了， 但是媽媽說了一個故事讓我們又笑了。 她說：您們小的時候，她曾經被您追 得爬到樹上去，真的嗎？ 雖然我個子小，但是我很強壯，
Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.
1.4 Sketching Intersections

1.4 Sketching Intersections

Similar presentations

Ads by Google